{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:03:42Z","timestamp":1770915822355,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Department of Science, Technology Project","award":["BL2014010"],"award-info":[{"award-number":["BL2014010"]}]},{"DOI":"10.13039\/100010677","name":"Science Foundation of Nanjing Public Health Bureau","doi-asserted-by":"publisher","award":["ZKX17025"],"award-info":[{"award-number":["ZKX17025"]}],"id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.diabres.2019.03.026","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T13:01:15Z","timestamp":1553086875000},"page":"194-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease"],"prefix":"10.1016","volume":"150","author":[{"given":"Yun","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing-li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diabres.2019.03.026_b0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.diabres.2019.03.026_b0010","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2019.03.026_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12944-016-0350-0","article-title":"Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials","volume":"15","author":"Shen","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"9","key":"10.1016\/j.diabres.2019.03.026_b0020","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000477820","article-title":"Role of glycyrrhizin in the reduction of inflammation in diabetic kidney disease","volume":"137","author":"Thakur","year":"2017","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0030","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s11255-016-1488-4","article-title":"Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: the Four Horsemen of the Apocalypse","volume":"49","author":"Turkmen","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0035","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/jcp.25429","article-title":"Anti-diabetic agent sodium tungstate induces the secretion of pro- and anti-inflammatory cytokines by human kidney cells","volume":"232","author":"Bertinat","year":"2017","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.diabres.2019.03.026_b0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2016.10.015","article-title":"Diabetic nephropathy and endothelial dysfunction: Current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study","volume":"166","author":"Leung","year":"2016","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.diabres.2019.03.026_b0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-017-0497-7","article-title":"The renal tubular damage marker urinary N-acetyl-beta-D-glucosaminidase may be more closely associated with early detection of atherosclerosis than the glomerular damage marker albuminuria in patients with type 2 diabetes","volume":"16","author":"Kim","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2019.03.026_b0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.12659\/MSM.899274","article-title":"Association between IL-18 and carotid intima-media thickness in patients with type II diabetic nephropathy","volume":"23","author":"Zhang","year":"2017","journal-title":"Med Sci Monit"},{"issue":"4","key":"10.1016\/j.diabres.2019.03.026_b0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"9725","key":"10.1016\/j.diabres.2019.03.026_b0060","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(10)60319-4","article-title":"Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies","volume":"375","author":"Thompson","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2019.03.026_b0065","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/156800605774962103","article-title":"Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis","volume":"5","author":"Zalewski","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"issue":"7","key":"10.1016\/j.diabres.2019.03.026_b0070","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2362.1997.1570706.x","article-title":"Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia","volume":"27","author":"Karabina","year":"1997","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ophtha.2014.12.014","article-title":"Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study","volume":"122","author":"Staurenghi","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.diabres.2019.03.026_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1476-511X-13-156","article-title":"The involvement of high mobility group 1 cytokine and phospholipases A2 in diabetic retinopathy","volume":"13","author":"Gong","year":"2014","journal-title":"Lipids Health Dis"},{"issue":"26","key":"10.1016\/j.diabres.2019.03.026_b0090","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.1073\/pnas.1514213113","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes","volume":"113","author":"Canning","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"10.1016\/j.diabres.2019.03.026_b0095","doi-asserted-by":"crossref","first-page":"e7671","DOI":"10.1097\/MD.0000000000007671","article-title":"Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients","volume":"96","author":"Ju","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157339910790909387","article-title":"Review of the relationship between renal and retinal microangiopathy in diabetes mellitus patients","volume":"6","author":"Romero-Aroca","year":"2010","journal-title":"Curr Diabetes Rev"},{"issue":"7","key":"10.1016\/j.diabres.2019.03.026_b0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2019.03.026_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.diabres.2019.03.026_b0115","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.diabres.2019.03.026_b0120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ndt\/15.7.994","article-title":"Increased blood levels of platelet-activating factor in insulin-dependent diabetic patients with microalbuminuria","volume":"15","author":"Cavallo-Perin","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0125","first-page":"1645","article-title":"Adiponectin regulates albuminuria and podocyte function in mice","volume":"118","author":"Sharma","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0130","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0020045","article-title":"Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy","volume":"2","author":"Susztak","year":"2005","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.diabres.2019.03.026_b0135","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.dsx.2018.11.022","article-title":"Assessing urinary levels of IL-18, NGAL and albumin creatinine ratio in patients with diabetic nephropathy","volume":"13","author":"Sueud","year":"2019","journal-title":"Diabetes Metab Syndr"},{"issue":"3","key":"10.1016\/j.diabres.2019.03.026_b0140","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/CS20120198","article-title":"Inflammation and the pathogenesis of diabetic nephropathy","volume":"124","author":"Wada","year":"2013","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1053\/meta.2003.50096","article-title":"Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy","volume":"52","author":"Moriwaki","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2019.03.026_b0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2840-12-21","article-title":"20\/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report","volume":"12","author":"Ohkura","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2019.03.026_b0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1582-4934.2002.tb00462.x","article-title":"Significance of platelet-activating factor acetylhydrolase in patients with non-insulin-dependent (type 2) diabetes mellitus","volume":"6","author":"Serban","year":"2002","journal-title":"J Cell Mol Med"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0160","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4158\/EP.13.2.147","article-title":"Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes","volume":"13","author":"Basu","year":"2007","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.diabres.2019.03.026_b0165","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2011-3026","article-title":"Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study","volume":"97","author":"Nelson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0170","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.atherosclerosis.2007.02.012","article-title":"Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment","volume":"196","author":"Iwase","year":"2008","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.diabres.2019.03.026_b0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jdiacomp.2006.07.004","article-title":"The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes","volume":"20","author":"Noto","year":"2006","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2019.03.026_b0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ki.2013.113","article-title":"NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy","volume":"84","author":"Du","year":"2013","journal-title":"Kidney Int"},{"issue":"Suppl 4","key":"10.1016\/j.diabres.2019.03.026_b0185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/nep.13182","article-title":"Clinical and pathological factors associated with progression of diabetic nephropathy","volume":"22","author":"Liang","year":"2017","journal-title":"Nephrology (Carlton)"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718316176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822718316176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:08:59Z","timestamp":1759172939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822718316176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":37,"alternative-id":["S0168822718316176"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2019.03.026","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2019.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}